Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones

被引:54
作者
Maccari, Rosanna
Ottana, Rosaria
Ciurleo, Rosella
Vigorita, Maria Gabriella
Rakowitz, Dietmar
Steindl, Theodora
Langer, Thierry
机构
[1] Univ Messina, Fac Pharm, Dipartimento Farmacochim, I-98168 Messina, Italy
[2] Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria
关键词
2,4-thiazolidinediones; aldose reductase; diabetes mellitus; molecular docking; DIABETIC COMPLICATIONS; REDUCTASE INHIBITORS; PREVENTION; TOLRESTAT; MELLITUS; LIGANDS; ENZYME; POTENT;
D O I
10.1016/j.bmcl.2007.04.109
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A number of 5-arylidene-2,4-thiazolidinediones containing a hydroxy or a carboxymethoxy group in their 5-benzylidene moiety have been synthesised and evaluated as in vitro aldose reductase (ALR2) inhibitors. Most of them exhibited strong inhibitory activity, with IC50 values in the range between 0.20 and 0.70 mu M. Molecular docking simulations into the ALR2 active site highlighted that the phenolic or carboxylic substituents of the 5-benzylidene moiety can favourably interact, in alternative poses, either with amino acid residues lining the lipophilic pocket of the enzyme, such as Leu300, or with the positively charged recognition region of the ALR2 active site. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3886 / 3893
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 2002, Chem-Bio Inform J, DOI DOI 10.1273/CBIJ.2.74
[2]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[3]   Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820
[4]   Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones [J].
Bruno, G ;
Costantino, L ;
Curinga, C ;
Maccari, R ;
Monforte, F ;
Nicolò, F ;
Ottanà, R ;
Vigorita, MG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (04) :1077-1084
[5]  
Castaner J., 1987, Drugs Future, V12, P336
[6]  
CHOU TC, 1996, CALCUSYN SOFTWARE VE
[7]   Pharmacological approaches to the treatment of diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Gamberini, MC ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262
[8]  
Costantino L, 1999, MED RES REV, V19, P3, DOI 10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.3.CO
[9]  
2-Z
[10]   New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Cignarella, G ;
Vianello, P ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (08) :843-858